FAETH THERAPEUTICS INC

FTHNASDAQ

🏆 #2483 by market capEarnings Nov 13US Equity

$29.86▼ $0.14 (−0.48%)

Live

1h▼ 0.2%

24h▼ 0.5%

7d▲ 22.1%

14d▲ 3.1%

30d▼ 13.0%

1y▲ 289.2%

🏦Market Cap

$770M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $29.41 – $30.23
52-Week Range: $13.43 – $37.90
Volume: $2.05B
Avg Volume: $2.43B
Shares Outstanding: 25.8M
Next Earnings: Oct 27, 2026

Fundamentals Snapshot

Annual Revenue: $91M
Last Q Revenue: $24M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-142.73
Dividend Yield: —

Why Investors Own FTH

✓High-growth profile — revenue up +18.6% YoY with expanding US Equity exposure.
✓Healthy economics — 43% gross margin and 26% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$91M▲ +22.6% YoY

Gross Margin (TTM)

42.7%▲ +2.1% YoY

Operating Income (TTM)

$20M▲ +22.6% YoY

Free Cash Flow (TTM)

$24M▲ +22.6% YoY

About FAETH THERAPEUTICS INC

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

🦦